Research published in the journal JAMA Oncology argues that major lifestyle changes can significantly delay the onset of cancer.
Research published in the journal JAMA Oncology argues that major lifestyle changes can significantly delay the onset of cancer.
To prove their hypothesis, the authors designed a prospective cohort study that analyzed cancer and lifestyle data from 3 sources:
The authors divided the all-white participants into 2 cohorts (89,571 women and 46,339 men)—low-risk group and high-risk group—based on whether they had a “healthy lifestyle” pattern. The low-risk group (healthy lifestyle) had to meet the following criteria:
The authors then estimated the proportion of cases and deaths of carcinomas (except skin, brain, lymphatic, hematologic, and nonfatal prostate malignancies) that could potentially be prevented by calculating the population-attributable risks (PARs). This was a comparison of incidence and mortality of total and major individual carcinomas between the 2 cohorts.
Only 16,531 women and 11,731 men fell in the low-risk group, the authors observed. The PARs for incidence and mortality of total carcinomas were 25% (low-risk) and 48% (high-risk) in women, and 33% (low-risk) and 44% (high-risk) in men. The following were the PARs statistics for the individual cancers:
Similar trends were observed for mortality, the authors report. The PARs were 4% and 12% for breast cancer incidence and mortality, and 21% for fatal prostate cancer.
These are significant numbers, considering that a majority of these cancers have very high mortality risks, primarily as a result of delayed detection due to a lack of specific symptoms. Based on their findings the authors believe that a substantial cancer burden can be prevented through lifestyle modification in the United States.
Reference
Song M, Giovannucci E. Preventable incidence and mortality of carcinoma associated with lifestyle factors among white adults in the United States. JAMA Oncol. 2016;2(9):1154-1161. doi: 10.1001/jamaoncol.2016.0843.
Real-World Study Reveals Key Insights into DLBCL Treatment Patterns, Outcomes
April 18th 2024A recent study offers valuable insights into the characteristics, treatment patterns, and outcomes of diffuse large B-cell lymphoma (DLBCL) in patients across different lines of therapy, providing a look into the landscape of DLBCL management.
Read More
Pegcetacoplan for PNH More Cost-Effective Than Anti-C5 Monoclonal Antibodies
April 18th 2024A cost-utility analysis conducted from the perspective of the Italian health system found that pegcetacoplan was more effective and less costly than 2 complement 5 (C5) inhibitors for the treatment of paroxysmal nocturnal hemoglobinuria (PNH).
Read More
Oncology Onward: A Conversation With Penn Medicine's Dr Justin Bekelman
December 19th 2023Justin Bekelman, MD, director of the Penn Center for Cancer Care Innovation, sat with our hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for our final episode of 2023 to discuss the importance of collaboration between academic medicine and community oncology and testing innovative cancer care delivery in these settings.
Listen
Many Patients With Psoriasis in Clinical Trials Experience Nocebo Effects, Study Finds
April 18th 2024Half of patients exposed to placebo in clinical trials experienced adverse events (AEs), which may be partially explainable by nocebo effects, according to a recent review and meta-analysis.
Read More
Low-Volume Hospitals Had Higher Reoperation Rate, Postoperative Complications in CRC
April 18th 2024Patients opting for elective colorectal surgery to address colorectal cancer (CRC) could have different rates of reoperation and postoperative complications based on the size of the hospital.
Read More